FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Currie Mark G 		2. Issuer Name and Ticker or Trading Symbol

Cyclerion Therapeutics, Inc. [ CYCN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President
(Last)          (First)          (Middle)

C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/1/2019
(Street)

CAMBRIDGE, MA 02142
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   4/1/2019     A    51648   (1) A $0.00   51648   D    
Common Stock   4/2/2019     P    270107   A $14.81   321755   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   $12.39   (2) 4/1/2019     A      888         (3) 2/2/2020   Common Stock   888   $0.00   888   D    
Employee Stock Option (Right to Buy)   $12.23   (2) 4/1/2019     A      37286         (3) 2/1/2021   Common Stock   37286   $0.00   37286   D    
Employee Stock Option (Right to Buy)   $16.21   (2) 4/1/2019     A      17491         (3) 2/1/2022   Common Stock   17491   $0.00   17491   D    
Employee Stock Option (Right to Buy)   $14.40   (2) 4/1/2019     A      27773         (3) 2/1/2023   Common Stock   27773   $0.00   27773   D    
Employee Stock Option (Right to Buy)   $15.54   (2) 4/1/2019     A      9930         (3) 3/3/2024   Common Stock   9930   $0.00   9930   D    
Employee Stock Option (Right to Buy)   $17.20   (2) 4/1/2019     A      13125         (3) 3/16/2025   Common Stock   13125   $0.00   13125   D    
Employee Stock Option (Right to Buy)   $17.20   (2) 4/1/2019     A      2500         (4) 3/16/2025   Common Stock   2500   $0.00   2500   D    
Employee Stock Option (Right to Buy)   $11.28   (2) 4/1/2019     A      50801         (5) 3/1/2026   Common Stock   50801   $0.00   50801   D    
Employee Stock Option (Right to Buy)   $18.46   (2) 4/1/2019     A      113430         (6) 2/27/2027   Common Stock   113430   $0.00   113430   D    
Employee Stock Option (Right to Buy)   $16.02   (2) 4/1/2019     A      141007         (7) 2/21/2028   Common Stock   141007   $0.00   141007   D    
Employee Stock Option (Right to Buy)   $14.20   (2) 4/1/2019     A      514786         (8) 1/29/2029   Common Stock   514786   $0.00   514786   D    

Explanation of Responses:
(1)  In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation.
(2)  Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation.
(3)  This option, granted as an annual performance award, is presently exercisable in full.
(4)  This option to purchase 25,212 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof.
(5)  The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016.
(6)  The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017.
(7)  The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018.
(8)  The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Currie Mark G
C/O CYCLERION THERAPEUTICS, INC.
301 BINNEY STREET
CAMBRIDGE, MA 02142

President

Signatures
/s/ Larry Miller, Attorney-in-Fact 4/3/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CYCLERION THERAPEUTICS, INC. (NASDAQ:CYCNV)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more CYCLERION THERAPEUTICS, INC. Charts.
CYCLERION THERAPEUTICS, INC. (NASDAQ:CYCNV)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more CYCLERION THERAPEUTICS, INC. Charts.